CannaThailand 2019

Please bring your confirmation letter to collect your badge

Why an industry association can help streamline the sector, and why it is taking so long?

Three legal observers from Thailand, Australia and the USA will share their views on what is coming, what is holding things back and what we have learned from other locations.
Speakers: Tilleke & Gibbins (TH), National Cannabis Industry Association (US)

Dr. Meiri is one of the pioneer researchers in the benefits of CBD. He will share achievement and promising opportunities for R&D. This session will tell us what we can expect on the Medical side in the next few decades.

In order to mainstream medical cannabis into traditional healthcare, it requires validation. To achieve this validation, the industry must approach it as it does traditional pharmaceutical drugs and apply the same protocols – using clinical trials to generate real-world data on the safety and efficacy of medical cannabis products and their delivery mechanisms. In CB2 Insights’ presentation, the company will discuss what is needed in order for medical cannabis to reach the commercialization stage and how companies will need to answer to the effectiveness of what they wish to market to patients and data to support cannabinoid treatment.

of knowledge extensive requires It. business complex a is facility greenhouse a Building in framework economic and product end, analysis climate, topography, type soil, crop the significant requires which, itself plant the, first,complexities more two have we Cannabis .extraction and removal leaf, curing, drying: processing harvest-post
form herbal its in used be can and smoked is, use medical for cultivated is plant the, Second exposed more is user the that meaning, materials active isolated through necessarily not and processing and cultivation entire the Hence. standardize to harder is product the and toxins to
.conditions sanitized highly and standards medical under out carried be to has procedure mostly is but countries between varies world the around regulation cannabis medical, Today standardization high requires and contamination any for tolerance low very having, strict very
.materials raw its and product the of traceability and
Good is demands these enforce to used is that standard quality common most the written Detailed. production of aspects all covers GMP). GMP (Practices Manufacturing documented provide which systems be must There. process each for essential are procedures the of step each at followed consistently are procedures correct the that ensure to proof .process manufacturing time-real with, greenhouses tech-high using by is result a such achieving of way main The light: including, parameters cultivation all over control and documentation, monitoring material all, facility harvest-post the In. diseases and pests, fertigation, humidity, temperature parameters cultivation the Because. standardized and controlled tightly be must flow work and in factor key a is technology of selection the, climate local on depend and variable are the Choosing. demands market and regulation meet to facility the of ability the determining design fixing as characterization preliminary detailed requires, design and technology proper impossible

"safety and efficacy" of treatments in the real world. As the distribution to patients is commencing, there are many lessons to be learned.

Share a table and a meal at the cafeteria and meet your fellow delegates

Tracking a unique experience and focus on creating a pipeline for global distribution of final dosage form medications with global market authorization.

Presentation by a representative of the Royal Thai Government

Cannabis can offer a great opportunity to small farmers. Will Thailand's experience in rice farming be translated to Cannabis allowing competitive opportunities for the rural farmers?